Financial Survey: OptiNose (NASDAQ:OPTN) vs. Bicara Therapeutics (NASDAQ:BCAX)

OptiNose (NASDAQ:OPTN) and Bicara Therapeutics (NASDAQ:BCAX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, institutional ownership, earnings, analyst recommendations, dividends and profitability.

Valuation & Earnings

This table compares OptiNose and Bicara Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OptiNose	$75.67 million	0.71	-$35.48 million	($4.20)	-1.28
Bicara Therapeutics	N/A	N/A	N/A	N/A	N/A

Bicara Therapeutics has lower revenue, but higher earnings than OptiNose.

Analyst Recommendations

This is a summary of current ratings and target prices for OptiNose and Bicara Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OptiNose	0	0	3	0	3.00
Bicara Therapeutics	0	0	7	1	3.13

OptiNose currently has a consensus price target of $16.67, suggesting a potential upside of 210.95%. Bicara Therapeutics has a consensus price target of $36.50, suggesting a potential upside of 193.89%. Given OptiNose’s higher possible upside, analysts plainly believe OptiNose is more favorable than Bicara Therapeutics.

Profitability

This table compares OptiNose and Bicara Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
OptiNose	-41.16%	N/A	-27.42%
Bicara Therapeutics	N/A	N/A	N/A

Institutional & Insider Ownership

85.6% of OptiNose shares are owned by institutional investors. 2.3% of OptiNose shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Bicara Therapeutics beats OptiNose on 5 of the 9 factors compared between the two stocks.

About OptiNose

OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania.

About Bicara Therapeutics

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.